as published in: |
|
our mission: stop the global rise of cardiometabolic & liver diseases
Dozens of large-scale population studies throughout the world show that higher C15:0 dietary intake and blood levels are associated with lower risks of some of the world's most devastating chronic diseases.
Paired with our extensive series of studies published in Scientific Reports, evidence is mounting around C15:0 as an essential micronutrient needed to slow the global pandemics of type 2 diabetes, cardiovascular disease, and liver disease.
In addition to these long-term benefits, C15:0 may provide near-term benefits, including improved mood, lowered caloric intake, and increased fat metabolism due to its role as an activator of key receptors (called PPARs) in our body that modulate metabolism, inflammation, appetite, and mood.
Keep reading below to learn more about how C15:0 may improve your long-term and short-term health. If you want to go straight to the full peer-reviewed scientific articles, please click here.
Paired with our extensive series of studies published in Scientific Reports, evidence is mounting around C15:0 as an essential micronutrient needed to slow the global pandemics of type 2 diabetes, cardiovascular disease, and liver disease.
In addition to these long-term benefits, C15:0 may provide near-term benefits, including improved mood, lowered caloric intake, and increased fat metabolism due to its role as an activator of key receptors (called PPARs) in our body that modulate metabolism, inflammation, appetite, and mood.
Keep reading below to learn more about how C15:0 may improve your long-term and short-term health. If you want to go straight to the full peer-reviewed scientific articles, please click here.
long-term health benefits associated with C15:0
Type 2 DiabetesNumerous studies have shown that people with higher circulating C15:0 concentrations have a lower risk having or developing type 2 diabetes. These studies were performed by prestigious research teams around the world, including Sweden, England, Canada, and Asia. One study showed that pregnant women with higher circulating C15:0 concentrations had a lower risk of developing gestational diabetes.
|
Cardiovascular DiseaseA nested case-control prospective study involving over 7,000 individuals followed for 13 years demonstrated that people with higher circulating C15:0 concentrations were less likely to develop coronary heart disease. Similar prospective cohort studies have shown that people with higher circulating C15:0 concentrations have a lower risk of developing cardiovascular disease and heart failure.
|
MortalityA case-control prospective study involving over 14,000 individuals followed for an average of 14 years showed that people (both men and women) who had higher dietary intake of odd-chain saturated fatty acids, including C15:0, had lower mortality rates. A similar association between higher circulating C15:0 concentrations and lower risk of all-cause mortality was found in a second study following over 4,000 people over 16 years. A study in Italy showed that people who lived in High Longevity Zones had higher circulating C15:0 concentrations compared to people living in Low Longevity Zones.
|
ObesityA case-control study involving 372 women showed that higher serum C15:0 concentrations are associated with lower adiposity.
|
Liver DiseaseMultiple studies have shown that people with higher circulating C15:0 concentrations have a lower risk of having nonalcoholic fatty liver disease (NAFLD) and severe nonalcoholic steatohepatitis, including children. NAFLD now affects 1 in 4 people, including 1 in 10 children, globally.
|
Lung DiseaseA cross-sectional study among patients with chronic obstructive pulmonary disease (COPD) showed a linear association between each increased milligram of dietary C15:0 ingested and improved lung function, measured as the FEV1/FVC.
|
Inflammation & ArthritisA cross-sectional study involving 484 people showed that higher serum C15:0 concentrations are associated with lower pro-inflammatory states. Another study evaluating a model of arthritis demonstrated that higher C15:0 concentrations in the serum and joint fluid was associated with a lower risk of joint degradation and osteoarthritis.
|
Metabolic SyndromeMetabolic syndrome is a cluster of conditions, including obesity, insulin resistance, hypertension, and dyslipidemia that is a precursor to type 2 diabetes, heart disease, and stroke. People with higher circulating C15:0 concentrations have a lower risk having or developing metabolic syndrome.
|
near-term C15:0 health benefits (as a ppar alpha/delta activator)
Since C15:0 naturally binds to and activates PPAR alpha and PPAR delta receptors, the following near-term health benefits may include:
Improved mood
PPAR alpha receptors are present in key parts of the brain involved in regulation of mood and emotions. Molecules that bind to PPAR alpha receptors can cause anti-depressant effects and improve mood.
|
Lowered caloric intake
PPAR alpha activators regulate body weight by suppressing appetite and decreasing one's caloric intake. Molecules that bind to PPAR alpha stimulate regions of the brain that control satiety as well as by increasing production of ketone bodies.
|
Increased fat metabolism
PPAR delta receptors are present throughout our body, including our fat. Molecules that bind to PPAR delta receptors increase the burning of fat by inducing fatty acid oxidation.
|